Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Relypsa Are Soaring Today

By George Budwell – Jul 21, 2016 at 12:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Swiss-based Galenica Group buys Relypsa for $1.53 billion in an all-cash deal.

Image Source: Getty Images.

What: Relypsa (RLYP), a biopharmaceutical company developing gastrointestinal medicines, saw its shares surge 58% higher at the opening bell today on the news that the Swiss-based Galenica Group bought the drugmaker in an all-cash deal for $32 per share, or about $1.53 billion. 

So what: Once this deal closes in the third quarter of this year, Galenica will gain access to Relypsa's FDA-approved treatment for hyperkalemia known as Veltassa (patiromer). Now that AstraZeneca's (AZN 0.06%) competing hyperkalemia therapy, ZS-9, has been rejected by the agency for manufacturing problems, Veltassa appears to be in prime position to take control of this nearly $6 billion market moving forward..

Perhaps the bigger issue is that some analysts initially pegged Veltassa's peak sales at a mere $200 million due to the presumed near-term entrance of Astra's rival drug. But with ZS-9 out of the picture for the time being, the Street now thinks Veltassa should have enough time as the go-to treatment to achieve blockbuster status.

Now what: Galenica plans to use the acquisition of Relypsa as a springboard to break the company up into two separate companies in 2017. Specifically, Relypsa will be rolled into Galenica's business unit Vifor Pharma, which is expected to be spun off into a publicly listed specialty pharmaceutical company focused on nephrology, cardiology, and gastroenterology medicines. So investors will presumably have yet another chance to invest in Relypsa's novel hyperkalemia drug by purchasing shares of the forthcoming spin-off next year. Stay tuned. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.21 (0.06%) $0.04
Relypsa, Inc. Stock Quote
Relypsa, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.